Medicus Pharma Ltd. Schedule 13G/A discloses that Ajay Raju (including related entities) beneficially owns 2,031,250 Common Shares, representing 3.7% of the class. The filing states 55,164,465 Common Shares outstanding as of April 30, 2026.
The holding consists of 2,000,000 shares held of record by 215 Capital Togo PHL Fund I, LP plus 31,250 shares underlying exercisable options. Voting and dispositive power is reported via Togo PHL Management LLC and Ajay Raju as managing member.
Medicus Pharma Ltd. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III information on directors, executive officers, governance and compensation. The filing confirms a nine‑member board with six standing committees and extensive biographies for each director and senior executive.
The company reports an aggregate market value of non‑affiliate common shares of approximately $28.3 million as of June 30, 2025, and 41,818,092 common shares outstanding as of April 15, 2026. Compensation tables disclose 2025 pay for four named executive officers, including salary, option awards and other compensation, along with option holdings and vesting values.
Medicus Pharma Ltd. amended its Equity Distribution Agreement with Maxim Group and Yorkville Securities to expand its at-the-market stock sales program from $15,349,674 to up to $50,000,000. The company has already raised about $11.5 million under this program.
Medicus also received a Nasdaq notice that its shares traded below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq’s minimum bid price rule. The company has 180 days, until October 19, 2026, for its closing bid to reach at least $1.00 for 10 straight business days to regain compliance.
Medicus Pharma Ltd. reported that Chief Operating Officer Smith Andrew Alasdair received a compensation grant of stock options. The award covers 50,000 options, each giving the right to buy one common share at an exercise price of $0.50 per share. The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, he holds 50,000 stock options directly.
Medicus Pharma Ltd. director Cathy McMorris Rodgers received a stock option grant covering 25,000 common shares. The options were awarded at an exercise price of $0.50 per share, carry no upfront cost, and expire on March 27, 2031. Following this grant, she holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Raju Ajay received a stock option grant for 25,000 common shares. The award gives him the right to buy 25,000 shares at an exercise price of $0.50 per share. The option becomes exercisable on March 26, 2027 and expires on March 27, 2031, and his directly held option position reported in this filing totals 25,000 derivative securities.
Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options as part of his compensation. The award covers 125,000 stock options, each exercisable for one common share at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this award, Faisal holds 125,000 stock options directly.
Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 25,000 underlying common shares. The options have an exercise price of $0.50 per share and can first be exercised on March 26, 2027.
These options expire on March 27, 2031. Following this grant, May Sara R. holds derivative securities representing 25,000 common shares, reflecting a compensation-related award rather than an open-market purchase.
Medicus Pharma Ltd. director Patrick J. Mahaffy received a compensation-related stock option grant, not an open-market trade. He was granted options to acquire 25,000 common shares at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this grant, he holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and are scheduled to expire on March 27, 2031. Following this award, he holds 25,000 derivative securities linked to Common Shares.